Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) – Investopedia

Posted: March 27, 2017 at 4:23 am


Investopedia
Novartis' Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)
Investopedia
has reported new data which suggests that its key psoriasis therapy, Cosentyx (secukinumab), has demonstrated the potential to modify the course of moderate-to-severe psoriasis, offering new hope of a more efficient treatment. Disease modification is ...
Threats And Opportunities In Psoriasis: What's Next For Novartis?Seeking Alpha
Novartis boasts a big new advantage for Cosentyx as data indicate the blockbuster can modify psoriasisEndpoints News
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially ...Yahoo Finance
PharmaTimes -Healio -pharmaphorum
all 11 news articles »

Excerpt from:
Novartis' Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) - Investopedia

Related Posts